NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹42.00.
| Holder | Stake |
|---|---|
| Rajasthan Global Securities | 3.90% |
| Document | Date |
|---|---|
| Annual report FY2026 NECTAR LIFESCIENCES LTD – ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Total Assets: ₹6,123.44 million (31 Mar 2026) vs ₹20,472.31 million (3 | 2026-08-20 |
| Quarterly results · Q1 FY27 NECTAR LIFESCIENCES LIMITED – DOCUMENT SUMMARY --- HEADLINE NUMBERS • Q1 FY2026-27 Standalone Results (Quarter ended June 30, 2026): - Total Inco | 2026-08-14 |
| Quarterly results · Q4 FY26 NECTAR LIFESCIENCES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Total Loss: ₹29,289.10 lakhs (consolidated), comprising ₹5,734.11 lakh | 2026-05-30 |
| Quarterly results · Q3 FY26 NECTAR LIFESCIENCES LTD – DOCUMENT SUMMARY HEADLINE NUMBERS • Document date: January 15, 2026 • Financial period under review: Quarter and six month | 2026-02-10 |
| Quarterly results · Q2 FY26 NECTAR LIFESCIENCES LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Quarter ended September 30, 2025 (Standalone - Continuing Operations Only): - R | 2025-11-14 |
| Quarterly results · Q1 FY26 NECTAR LIFESCIENCES LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Company has one wholly owned subsidiary: NECLIFE PT, UNIPESSOAL LDA (Portugal-base | 2025-09-10 |
| Annual report FY2025 NECTAR LIFESCIENCES LIMITED – ANNUAL REPORT FY 2024-25 SUMMARY HEADLINE NUMBERS • Revenue from Operations (Net of GST): ₹16,699.74 million (FY24: ₹1 | 2025-08-26 |
| Quarterly results | 2025-05-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Update on acquisition of another business or entity Nectar Lifesciences Limited has informed the Exchange about Update on Acquisition | 2026-03-06 |
| Acquisition of another business announced Nectar Lifesciences Limited has informed the Exchange about Acquisition | 2026-03-02 |
| Post Buyback Public Announcement regarding share repurchase program Nectar Lifesciences Limited has informed the Exchange about post Buyback Public Announcement | 2026-01-15 |
| Letter of offer for buyback of equity shares announced Nectar Lifesciences Limited has informed the Exchange about letter of offer for Buyback of equity shares of the Company | 2025-12-29 |
| Corrigendum issued for public announcement regarding share buyback program Nectar Lifesciences Limited has informed the Exchange about corrigendum for public Announcement - Buyback of Shares | 2025-12-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nectar Lifesciences Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.